ENZON PHARMACEUTICALS Amends Securities Registration (8-A12G/A)
Ticker: ENZN · Form: 8-A12G/A · Filed: Mar 24, 2026 · CIK: 0000727510
Complexity: simple
Sentiment: neutral
Topics: compliance, registration, amendment, regulatory
TL;DR
**ENZON PHARMACEUTICALS just updated their public stock registration, keeping shares tradable.**
AI Summary
ENZON PHARMACEUTICALS, INC. (CIK: 0000727510) filed an amended Form 8-A12G/A on March 24, 2026, to register its securities under Section 12(g) of the Securities Exchange Act of 1934. This filing, with File No. 000-12957, indicates a change or update to their previous registration statement, likely related to ensuring their shares can be publicly traded and reported. For investors, this means the company is maintaining its compliance with SEC regulations, which is crucial for the liquidity and transparency of their stock.
Why It Matters
This filing ensures ENZON PHARMACEUTICALS, INC. remains compliant with SEC regulations for publicly traded securities, which is fundamental for investor confidence and market access.
Risk Assessment
Risk Level: low — This is a routine compliance filing and does not indicate any immediate financial risk or opportunity.
Analyst Insight
Investors should view this as a routine compliance update, confirming the company's adherence to regulatory requirements for public trading. No immediate investment action is suggested by this filing alone.
Key Numbers
- 0000727510 — CIK (Unique identifier for ENZON PHARMACEUTICALS, INC.)
- 2026-03-24 — Filing Date (Date the 8-A12G/A was filed)
- 000-12957 — File No. (SEC file number for this registration)
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — the filer of the 8-A12G/A form
- 0000727510 (company) — CIK of ENZON PHARMACEUTICALS, INC.
- 2026-03-24 (date) — filing date of the 8-A12G/A
- Section 12(g) (other) — section of the Securities Exchange Act of 1934 under which securities are registered
- 000-12957 (other) — File Number for the registration
FAQ
What is the purpose of ENZON PHARMACEUTICALS, INC.'s 8-A12G/A filing?
The 8-A12G/A filing by ENZON PHARMACEUTICALS, INC. is an amendment to the registration of its securities under Section 12(g) of the Securities Exchange Act of 1934, indicating an update or change to their public registration.
When was this 8-A12G/A filing accepted by the SEC?
This 8-A12G/A filing was accepted by the SEC on March 24, 2026, at 08:33:09.
Filing Stats: 2,181 words · 9 min read · ~7 pages · Grade level 10 · Accepted 2026-03-24 08:33:09
Filing Documents
- tm267492d17_8a12ga.htm (8-A12G/A) — 38KB
- 0001104659-26-033626.txt ( ) — 39KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A Amendment No. 11 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ENZON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 22-2372868 (I.R.S. Employer Identification No.) 20 Commerce Drive (Suite 135), Cranford, New Jersey (Address of principal executive offices) 07016 (Zip Code) Securities to be registered pursuant to Section 12(b) of the Act: None. Title of each class to be so registered Name of each exchange on which each class is to be registered N/A N/A If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. Securities Act registration statement or Regulation A offering statement file number to which this form relates: Not applicable. Securities to be registered pursuant to Section 12(g) of the Act: Series A-1 Junior Participating Preferred Stock Purchase Rights (Title of Class) EXPLANATORY NOTE This Amendment No. 11 to Form 8-A is filed to amend and supplement Items 1 and 2 of the Registration Statement on Form 8-A filed by Enzon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), with the U.S. Securities and Exchange Commission (the “ SEC ”) on August 14, 2020, as amended by Amendment No. 1 to Form 8-A filed with the SEC on June 8, 2021, Amendment No. 2 to Form 8-A filed with the SEC on May 22, 2024, Amendment No. 3 to Form 8-A filed with the SEC on April 1, 2025, Amendment No. 4 filed with the SEC on August 14, 2025, Amendment No. 5 to Form 8-A filed with the SEC on September 30, 2025, Amendment No. 6 to Form 8-A filed with the SEC on December 23, 2025, Amendment No. 7 to Form 8-A filed with the SEC on January 30, 2026, Amendment No. 8 to Form 8-A filed with the SEC on February 27, 2026, Amendment No. 9 to Form 8-A filed with the SEC on March 11, 2026, and Amendment No. 10 to the Form 8-A filed with the SEC on March 18, 2026. Item 1. Description of Registrant’s Securities to be Registered. On March 23, 2026, the Company entered into the Eleventh Amendment to the Section 382 Rights Agreement (the “ Eleventh Amendment ”), which amends the Section 382 Rights Agreement, dated as of August 14, 2020 (the “ Rights Agreement ”), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent. Effective as of June 2, 2021, the Company amended the Rights Agreement (the “ First Amendment ”) to extend the Final Expiration Date (as defined in the Rights Agreement) of the rights issued pursuant to the Rights Agreement from the close of business on August 13, 2021 to the close of business on June 2, 2024. Effective as of May 16, 2024, the Company amended the Rights Agreement (the “ Second Amendment ”) to extend the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on June 2, 2024 to the close of business on March 31, 2025. Effective as of March 31, 2025, the Company entered into the Third Amendment (the “ Third Amendment ”) to extend the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on March 31, 2025 to the close of business on June 30, 2026. Effective as of August 13, 2025, the Company amended the Rights Agreement (the “ Fourth Amendment ”) to adjust the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on June 30, 2026 to the close of business on September 30, 2025. Effective as of September 30, 2025, the Company amended the Rights Agreement (the “ Fifth Amendment ”) to adjust the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on September 30, 2025 to the close of business on December 31, 2025. Effective as of December 23, 2025, the Company amended the Rights Agreement (the “ Sixth Amendment ”) to adjust the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on December 31, 2025 to the close of business on January 31, 2026. Effective as of January 30, 2026, the Company amended the Rights Agreement (the “ Seventh Amendment ”) to adjust the Final Expiration Date of the rights issued pursuant to th